Top in cardiology: Sacubitril/valsartan, refined grain consumption

The FDA has granted an expanded indication for sacubitril/valsartan in adult patients with chronic heart failure, according to the manufacturer. The announcement was the top story in cardiology last week.

Another top story was about new data from an international study that showed refined grain consumption was associated with an increased risk for mortality and cardiovascular events.

Read these and more top stories in cardiology below:

Sacubitril/valsartan receives expanded indication, including for some with HFpEF

Novartis announced the FDA has granted an expanded indication for sacubitril/valsartan to lower risk for cardiovascular death and heart failure hospitalization in adult patients with chronic heart failure. Read more.

Refined grain consumption associated with increased risk for mortality, CVD events

Refined grain consumption was associated with an increased risk for mortality and major CVD events, according to new data from the PURE study published in The BMJ. Read more.

ACC publishes recommendations for COVID-19 vaccine prioritization

COVID-19 vaccine prioritization should focus on patients with severe CVD rather than those who are well-managed, according to a health policy statement from the American College of Cardiology. Read more.

Lower levels of elevated BP more harmful in women vs. men

In women, systolic BP as low as 100 mm Hg to 109 mm Hg may be associated with CVD risk, according to a study published in Circulation. Read more.

Myocardial injury common in patients with severe COVID-19 months after discharge

Using cardiac MRI, researchers found myocardial injury in more than half of patients hospitalized with severe COVID-19 and elevated troponin a few months after hospital discharge. Read more.